Multiple myeloma: a review

Stevenson, J.D.; Wall, Claudia de; Patel, Akash D; Lim, Ji Hong

doi:10.1016/j.mporth.2014.05.007

Cited by 4 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients' median age at the time of diagnosis is around 65 years old 6 . The marrow‐containing bones of the vertebrae, pelvis, and femur are the most prevalent sites for MM, but lesions can occur in any bone 3 . The majority of tumor cells are restricted to the bone marrow.…”

Section: Discussionmentioning

confidence: 99%

“…14 On the other hand, MRI has been established as the imaging modality of choice when diagnosing MM by numerous studies. 3,4,5,13 MRI can show cell infiltration in the bone marrow which could indicate the presence of MM. The IMWG recently updated the MRI indication for diagnosing MM by increasing the number of focal lesions present on the image that are greater than 5 mm.…”

Section: Discussionmentioning

confidence: 99%

“…6 The marrow-containing bones of the vertebrae, pelvis, and femur are the most prevalent sites for MM, but lesions can occur in any bone. 3 The majority of tumor cells are restricted to the bone marrow. However, malignant plasma cells can break through the bone marrow and periosteal tissue, creating tumorous masses in the nearby bone site.…”

Section: Discussionmentioning

confidence: 99%

“…Multiple myeloma (MM) is hematological cancer characterized by the growth of malignant plasma cells of B‐cell lineage which are found in the bone marrow and secrete immunoglobulins (Ig), 1–3 The illness mostly affects the bones, although it can also affect the lymphatic nodes and epidermis. MM is an incurable disease, 3 which is also one of the most prevalent cancers that affect the spine 4 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A rare multiple myeloma complication as a spinal cord metastasis: A case report

Mansour¹,

Haider

Khiami

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A rare multiple myeloma complication as a spinal cord metastasis: A case report

Mansour¹,

Haider

Khiami

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Multiple myeloma is the second most common hematological malignancy characterized by pathological PC accumulation in BM with an incidence rate of 4.8 cases per 100,000 people in the Czech Republic [70], and 1.5 cases per 100,000 people worldwide [71]. MM is preceded by asymptomatic precancerosis MGUS with a risk of progression of 1% per year [72]. Events causing progression into MM are not clear, but genetic abnormalities, including mutations of tumor suppressors or oncogenes play an important role [73].…”

Section: Long Non-coding Rnas In Multiple Myelomamentioning

confidence: 99%

Long Non-Coding RNAs in Multiple Myeloma

Bútová

Vychytilova-Faltejskova

Souckova

et al. 2019

ncRNA

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most common hematooncological disease of malignant plasma cells in the bone marrow. While new treatment brought unprecedented increase of survival of patients, MM pathogenesis is yet to be clarified. Increasing evidence of expression of long non-coding RNA molecules (lncRNA) linked to development and progression of many tumors suggested their important role in tumorigenesis. To date, over 15,000 lncRNA molecules characterized by diversity of function and specificity of cell distribution were identified in the human genome. Due to their involvement in proliferation, apoptosis, metabolism, and differentiation, they have a key role in the biological processes and pathogenesis of many diseases, including MM. This review summarizes current knowledge of non-coding RNAs (ncRNA), especially lncRNAs, and their role in MM pathogenesis. Undeniable involvement of lncRNAs in MM development suggests their potential as biomarkers.

show abstract

The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)

et al. 2018

View full text Add to dashboard Cite

We conducted a prospective study of 312 patients (194 with multiple myeloma, 118 with lymphomas) receiving high-dose conditioning chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT). Polymorphisms of MBL2 and MASP2 genes were investigated and serial measurements of serum concentrations of mannose-binding lectin (MBL), CL-LK collectin and MASP-2 as well as activities of MBL-MASP-1 and MBL-MASP-2 complex were made. Serum samples were taken before conditioning chemotherapy, before HSCT and once weekly after (totally 4-5 samples); in minority of subjects also 1 and/or 3 months post transplantation. The results were compared with data from 267 healthy controls and analyzed in relation to clinical data to explore possible associations with cancer and with chemotherapy-induced medical complications. We found a higher frequency of MBL deficiency-associated genotypes (LXA/O or O/O) among multiple myeloma patients compared with controls. It was however not associated with hospital infections or post-HSCT recovery of leukocytes, but seemed to be associated with the most severe infections during follow-up. Paradoxically, high MBL serum levels were a risk factor for prolonged fever and some infections. The first possible association of MBL2 gene 3′-untranslated region polymorphism with cancer (lymphoma) in Caucasians was noted. Heterozygosity for MASP2 gene +359 A>G mutation was relatively frequent in lymphoma patients who experienced bacteremia during hospital stay. The median concentration of CL-LK was higher in myeloma patients compared with healthy subjects. Chemotherapy induced marked increases in serum MBL and MASP-2 concentrations, prolonged for several weeks and relatively slighter decline in CL-LK level within 1 week. Conflicting findings on the influence of MBL on infections following chemotherapy of myeloma and lymphoma have been reported. Here we found no evidence for an association between MBL deficiency and infection during the short period of neutropenia following conditioning treatment before HSCT. However, we noted a possible protective effect of MBL during follow-up, and suspected that to be fully effective when able to act in combination with phagocytic cells after their recovery.

show abstract

Multiple myeloma: a review

Cited by 4 publications

References 26 publications

A rare multiple myeloma complication as a spinal cord metastasis: A case report

A rare multiple myeloma complication as a spinal cord metastasis: A case report

Long Non-Coding RNAs in Multiple Myeloma

The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT)

Contact Info

Product

Resources

About